165 related articles for article (PubMed ID: 18413420)
41. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
Hansen TB; Gram J; Jensen PB; Kristiansen JH; Ekelund B; Christiansen JS; Pedersen FB
Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
[TBL] [Abstract][Full Text] [Related]
42. The effect of a period of intense exercise on the marker approach to detect growth hormone doping in sports.
Voss SC; Robinson N; Alsayrafi M; Bourdon PC; Schumacher YO; Saugy M; Giraud S
Drug Test Anal; 2014 Jun; 6(6):582-6. PubMed ID: 24827554
[TBL] [Abstract][Full Text] [Related]
43. The International Olympic Committee (IOC) and GH-2000.
Sönksen P
Growth Horm IGF Res; 2009 Aug; 19(4):341-5. PubMed ID: 19473864
[TBL] [Abstract][Full Text] [Related]
44. Effects of intensive chemotherapy on bone and collagen turnover and the growth hormone axis in children with acute lymphoblastic leukemia.
Crofton PM; Ahmed SF; Wade JC; Stephen R; Elmlinger MW; Ranke MB; Kelnar CJ; Wallace WH
J Clin Endocrinol Metab; 1998 Sep; 83(9):3121-9. PubMed ID: 9745414
[TBL] [Abstract][Full Text] [Related]
45. [Growth hormone and IGF-1 as doping agents in competitive sport].
Jóźków P; Medraś M
Endokrynol Pol; 2009; 60(5):389-94. PubMed ID: 19885810
[TBL] [Abstract][Full Text] [Related]
46. Age-dependent impairment of endothelial progenitor cells is corrected by growth-hormone-mediated increase of insulin-like growth-factor-1.
Thum T; Hoeber S; Froese S; Klink I; Stichtenoth DO; Galuppo P; Jakob M; Tsikas D; Anker SD; Poole-Wilson PA; Borlak J; Ertl G; Bauersachs J
Circ Res; 2007 Feb; 100(3):434-43. PubMed ID: 17234973
[TBL] [Abstract][Full Text] [Related]
47. Detecting growth hormone abuse in athletes.
Bidlingmaier M; Manolopoulou J
Endocrinol Metab Clin North Am; 2010 Mar; 39(1):25-32, vii. PubMed ID: 20122447
[TBL] [Abstract][Full Text] [Related]
48. IGF-I abuse in sport.
Guha N; Dashwood A; Thomas NJ; Skingle AJ; Sönksen PH; Holt RI
Curr Drug Abuse Rev; 2009 Sep; 2(3):263-72. PubMed ID: 20443773
[TBL] [Abstract][Full Text] [Related]
49. Longitudinally monitoring of P-III-NP, IGF-I, and GH-2000 score increases the probability of detecting two weeks' administration of low-dose recombinant growth hormone compared to GH-2000 decision limit and GH isoform test and micro RNA markers.
Lehtihet M; Bhuiyan H; Dalby A; Ericsson M; Ekström L
Drug Test Anal; 2019 Mar; 11(3):411-421. PubMed ID: 30223291
[TBL] [Abstract][Full Text] [Related]
50. Growth hormone, IGF-I and insulin and their abuse in sport.
Holt RI; Sönksen PH
Br J Pharmacol; 2008 Jun; 154(3):542-56. PubMed ID: 18376417
[TBL] [Abstract][Full Text] [Related]
51. Erythropoietin administration does not influence the GH--IGF axis or makers of bone turnover in recreational athletes.
Nelson AE; Howe CJ; Nguyen TV; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
Clin Endocrinol (Oxf); 2005 Sep; 63(3):305-9. PubMed ID: 16117818
[TBL] [Abstract][Full Text] [Related]
52. Serum leptin response to the acute and chronic administration of growth hormone (GH) to elderly subjects with GH deficiency.
Gill MS; Toogood AA; Jones J; Clayton PE; Shalet SM
J Clin Endocrinol Metab; 1999 Apr; 84(4):1288-95. PubMed ID: 10199769
[TBL] [Abstract][Full Text] [Related]
53. Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.
Equey T; Pastor A; de la Torre Fornell R; Thomas A; Giraud S; Thevis M; Kuuranne T; Baume N; Barroso O; Aikin R
J Clin Endocrinol Metab; 2022 Feb; 107(3):649-659. PubMed ID: 34726230
[TBL] [Abstract][Full Text] [Related]
54. Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing.
Weiss S; Henle P; Bidlingmaier M; Moghaddam A; Kasten P; Zimmermann G
Growth Horm IGF Res; 2008 Jun; 18(3):205-12. PubMed ID: 17936052
[TBL] [Abstract][Full Text] [Related]
55. The intra-individual stability of GH biomarkers IGF-I and P-III-NP in relation to GHRH administration, menstrual cycle, and hematological parameters.
Ericsson M; Bhuiyan H; Yousif B; Lehtihet M; Ekström L
Drug Test Anal; 2020 Nov; 12(11-12):1620-1628. PubMed ID: 33125822
[TBL] [Abstract][Full Text] [Related]
56. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism.
Colao A; Di Somma C; Pivonello R; Loche S; Aimaretti G; Cerbone G; Faggiano A; Corneli G; Ghigo E; Lombardi G
J Clin Endocrinol Metab; 1999 Jun; 84(6):1919-24. PubMed ID: 10372687
[TBL] [Abstract][Full Text] [Related]
57. A correction to the age-adjustment of the GH-2000 score used in the detection of growth hormone misuse.
Böhning D; Böhning W; Guha N; Cowan DA; Bartlett C; Sönksen PH; Holt RIG
BMC Res Notes; 2018 Sep; 11(1):650. PubMed ID: 30185229
[TBL] [Abstract][Full Text] [Related]
58. Procollagen type III amino-terminal propeptide and insulin-like growth factor I as biomarkers of growth hormone administration.
Cowan DA; Moncrieffe DA
Drug Test Anal; 2022 May; 14(5):808-819. PubMed ID: 34418311
[TBL] [Abstract][Full Text] [Related]
59. Growth hormone in sports: detecting the doped or duped.
Ho KK; Nelson AE
Horm Res Paediatr; 2011; 76 Suppl 1():84-90. PubMed ID: 21778756
[TBL] [Abstract][Full Text] [Related]
60. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
